Common human virus may be associated with colon cancer, according to Temple researchers

November 30, 2002

An association between a common human virus and colon cancer has been established by a group of researchers from Temple University, suggesting a possible role for it in the development of cancer in the human intestinal tract.

Their study, "Association of Human Polyomavirus JCV with Colon Cancer: Evidence for Interaction of Viral T-Antigen and -catenin," appears in the Dec. 1 issue of Cancer Research.

Kamel Khalili, Ph.D., professor and director of Temple's Center for Neurovirology and Cancer Biology, and his co-investigators found the viral genome and viral proteins T-antigen and Agnoprotein in samples of malignant epithelial tumors in the large intestine, which may play a role in the development of the intestinal tract tumors.

"There is a human virus, called JC virus (JCV), which infects greater than 90 percent of the human population worldwide, usually during early childhood," says Khalili, the study's lead researcher.

According to Khalili, the JC virus most likely infects humans through the upper respiratory tract and remains in a latent stage in most people throughout their lives, and, in some cases, causes minor sub-clinical problems. However, in people whose immune systems are depressed, either through chemotherapy given to organ transplant recipients or an illness such as AIDS, JCV can become active and may contribute to cancer in the brain or cause the fatal demyelinating disease Progressive Multifocal Leukoencephalopathy (PML).

Khalili says that the current study suggests that, in addition to respiratory transmission, the virus may enter into the human population orally through contaminated food or water.

"What's interesting is that other studies have shown that this virus is present in raw sewage," says Khalili. "In fact, JC virus particles survive in the sewage. This suggests that we may get re-infected with the virus later on in life as well. Re-infection of the human population through contaminated water or food can take the virus into different organs, which in this case may be the intestinal tract. "

Khalili says that once in the intestinal tract, the genome of the JC virus expresses the viral protein T-antigen, which has oncogenic potential, and it associates with ß-catenin, an important protein for controlling cell division and balancing many of the normal biological events that occur in cells.

"ß-catenin's role in colon cancer has been previously suggested," says Khalili. "In this study, it seems T-antigen associates with ß-catenin and deregulates its function, and it's this deregulation that is causing induction of the tumors."

Khalili and the researchers used state-of-the-art laser micro-dissection to remove both cancerous and normal cells from the colon tissue and analyze them for JC virus genomic DNA.

Results from the gene amplification revealed the presence of the viral early genome in 22 of the 27 tumors sampled, and the expression of the viral proteins T-antigen and Agnoprotein was observed in more than 50 percent of the samples.

"Since its discovery almost 50 years ago, we thought that the JC virus was only expressed in cells of the nervous system," says Khalili.

"But in this study we are showing that the virus can also express its genes in non-neural tissue, which in this case is intestinal.

"What we show in this study, and our previous studies that showed an association between JCV and pediatric brain tumors, is that the JC virus has the ability to do more than just cause PML," adds Khalili, who has been studying the molecular biology of the JC virus for nearly two decades. "We have a virus in our body which may be involved in causing tumors."

Khalili says that the questions now facing researchers are whether or not the JC virus actually causes tumors; whether the tumors formed because of other elements and the virus helped as a co-factor; or whether something else causes the tumors and the presence of the virus is a mere coincidence.

"We're not saying every single tumor is being induced by the JC virus, because when you detect a virus in a tumor, you cannot actually say the virus causes it," Khalili cautions. "What we are stating is that the virus can be detected in a good number of the human colon cancer tumors we sampled, and the product of the virus, the viral protein T-antigen, which has oncogenic potential, can be detected in those tumor cells."

Khalili says that the discovery of the association between JCV and tumors is important for therapeutic and treatment reasons. "We can start developing strategies and vaccines against JC virus, which will hopefully lead to the prevention of the tumors it may induce," he says.
-end-
News Media Contact: Preston Moretz, Science Writer, Temple University Office of News and Media Relations. Office: 215-204-7476, Home: 215-288-8315, Cell: 215-850-1974, or pmoretz@temple.edu.

Attribution to Cancer Research and Temple University's Center for Neurovirology and Cancer Biology is requested in all news coverage.

NOTE: A downloadable copy of this news release, along with color illustrations, is available online at http://www.temple.edu/news_media/pm484.html.

About Temple's Center for Neurovirology and Cancer Biology:

The Center for Neurovirology and Cancer Biology is a state-of-the-art multidisciplinary research and education facility in Temple University's College of Science and Technology. The goals and objectives of the Center are to perform cutting edge research on the molecular biology, genetics and biochemistry of viral and non-viral induced neurological disorders in order to facilitate development of molecular therapeutics strategies against relevant diseases; and train first-rate scientists/educators in the field of modern biology who will successfully develop new ideas and technologies to further the field of biomedical life sciences and medical research. For more information, visit the Center's website at www.temple.edu/cnvcb.

Temple University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.